Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
 93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 67-year-old woman suffered from an ovarian carcinoma with lymph nodes metastasis. During 3 years, she was treated with alkylating agents (Melphalan). At the end of therapy, no recurrence was observed. Two years later, she developed concomitantly pyoderma gangrenosum and acute myelomonocytic leukaemia. Death occurred rapidly. The association between pyoderma gangrenosum and acute leukaemia is discussed in the light of 16 cases previously reported in the literature. In this case, an induction of leukaemia by cytostatic drugs seems likely. The authors conclude that pyoderma gangrenosum may be considered as a cutaneous signs of acute leukaemia.
Ann Dermatol Venereol 1979 Mar
PMID:[Pyoderma gangrenosum, ovarian carcinoma treated with Melphalan and acute myelomonocytic leukaemia: report of one case and literature review (author's transl)]. 29 Mar 49

A patient developed a cutaneous deposit of leukaemic cells within a squamous cell carcinoma as the first presentation of acute myeloblastic leukaemia.
Br J Dermatol 1979 Aug
PMID:Cutaneous acute myeloblastic leukaemia and squamous cell carcinoma. 29 Mar 81

Scleromyxedema is an uncommon cutaneous fibromucinous disease with a monoclonal protein, which has resisted a number of therapies. Eight cases followed up for as long as 12 years have provided an opportunity to observe the effects of melphalan treatment in this disease. The fibrohistiocytic and mucinous change of the skin in scleromyxedema and often the monoclonal protein can be controlled by low-dose chemotherapy. Although melphalan does not usually produce clinical toxic effects of importance, it is a myelotoxic drug and cytopenia is common; one patient died of acute myelomonocytic leukemia after ten years of successful therapy of the scleromyxedema, thus implying that long-term therapy may be dangerous by itself. These patients require close supervision. Leukocyte and platelet counts must be performed every three weeks, and the dosage of melphalan adjusted accordingly.
Arch Dermatol 1979 Mar
PMID:Treatment of scleromyxedema with melphalan. 43 43

Of 2,141 patients with scleroderma who were seen at the Mayo Clinic, Rochester, Minn, between 1959 and 1975, 78 had 87 internal malignancies. The relative frequency of the types of cancers was similar to that for the general population. The increased numbers of patients with breast and uterine carcinomas were consistent with the female preponderance in scleroderma. Contrary to previous reports, carcinoma of the lung was not the most frequent malignancy associated with scleroderma. The lymphoma-leukemia malignancies were second only to breast carcinoma in frequency, comprising about 17% of the malignancies. Both conditions developed within a three-year period in 68% (45/66) of our patients affected with systemic scleroderma, and this subgroup comprised a high mortality group. This study is not an epidemiologic one in the strictest sense, but it is a review of the experience of the Mayo Clinic with patients who have had both scleroderma and an internal malignancy.
Arch Dermatol 1979 Aug
PMID:Cancer and scleroderma. 46 24

The authors report three personal cases of phagedenic pyoderma associated with hemopathy. Studying twenty-five other cases, described in the reviews, the question can be debated on three levels: 1) The clinical characteristics of hemopathic pyoderma remain non-specific. However blisters, pustules, and even vegetating lesions occur very often; 2) the etiology of hemopathy is subject to change; acute leukaemia or myeloproliferation syndrome. During the polyglobulars associated with pyoderma, anemia and myelofibrosis appear quite constantly; 3) finally on the pathogenic level, the recent works tend towards the hypothesis of a damage in the functioning of the polymorphonuclears hence displaying the increase in the inflammation during phagedenic pyoderma.
Ann Dermatol Venereol 1979 May
PMID:[Pyoderma gangrenosum and haemopathy. Report of three cases (author's transl)]. 49 6

Primary cutaneous aspergillosis is rare. In this report we describe a primary skin infection by Aspergillus flavus in a child with leukemia. The lesions were characterized by erythematous macules and papules associated with pain and itching, followed by a rapid progression to ulcers and central black eschars with a raised erythematous border. A favorable response to topical nystatin therapy was observed. The multiple cutaneous lesions seen in our patient were most likely due to primary inoculation near the site of intravenous infusion with subsequent local lymphatic spread.
Arch Dermatol 1978 Jan
PMID:Primary cutaneous aspergillosis in a leukemic child. 61 88

The clinical course of a patient with acute lymphoid immunoblastic leukaemia and prominent nodular haemorrhagic skin lesions is described. Cytological, cytochemical and electronmicroscopic studies were performed on bone marrow and skin blast cells. The absence of surface immunoglobulins and of the other markers for B lymphocytes (EA and EAC rosettes) and the presence of 30% of spontaneous sheep erythrocyte rosettes excluding an acute leukaemia with Burkitt's tumour cells, suggest that T cells are involved. Complete haematological and cutaneous remission was obtained with prednisone therapy.
Br J Dermatol 1976 Jul
PMID:Leucosis and skin: acute lymphoid immunoblastic leukaemia. 78 3

Most attempts to prolong the survival of allografts have involved treatment of the host to impair its capacity to reject them. Early uncritical attempts to treat the graft rather than the host were received with skepticism because of the prevailing belief that the alloantigens on cell surfaces are immutable. However, over the past decade unequivocal evidence has accumulated that the immunogenicity of allografts is susceptible to alteration. Short-term maintenance in vitro of malignant and normal tissue grafts, such as those of the ovary and thyroid. Weakens their susceptibility to rejection. Various agents have been identified which, when applied to tissues or organs in vitro, have a similar effect. Soaking skin in media containing steroids, urethane, thalidomide, antilymphocyte globulin (ALG), and specific alloantibody is also effective. X-irradiation and perfusion of allogeneic dog kidneys with solutions of concanavalin A or of nucleic acid prepared from the future donor or even from indifferent donors or microoorganisms lead to extended survival. There is also equivocal evidence that soaking mouse skin grafts in RNA prepared from unrelated donors causes them to be treated as allogeneic by syngeneic recipients. Skin from animals suffering from certain diseases displays altered immunogenicity. Skin from mice suffering from virus-induced leukemia or lymphocytic choriomeningitis is frequently rejected by syngeneic recipients. By contrast, skin allografts from some cancer patients and from mice bearing certain tumors give evidence of prolonged survival as do grafts from uremic mice. Some treatments of prospective donors, including cytotoxic drugs, ALG, specific alloantisera, hypoxia, and experimentally produced uremia, also extend the lives of allografts. Trophoblast, a fetal epithelial tissue in immediate contact with maternal tissue, represents a natural example of graft adaptation. Despite its origin from precursor cells with normal transplantation properties, trophoblast fails to elicit transplantation immunity and is unaffected by it. Some of the disparate agents or procedures described here probably act by modifying grafts in such a way that they are more likely to evoke "blocking" or enhancing antibodies rather than the usual destructive cellular immunity, and many of them deplete the grafts of immunogenically effective "passenger" leukocytes. Both of these processes contribute to apparent hypoantigenicity.
J Invest Dermatol 1976 Jul
PMID:The feasibility of altering the immunogenicity of grafts. 81 91

Pyoderma gangrenosum has been associated with myelogenous leukemia and plasma cell dyscrasia. When associated with leukemia, pyoderma gangrenosum often has a distinctive clinical presentation with an advancing bullous margin. The pathogenesis of this disorder is unknown, although defective immune mechanisms may be operative. The occurrence of pyoderma gangrenosum and agnogenic myeloid metaplasia in the same patient has now been reported sufficiently to make it a recognized association.
Arch Dermatol 1977 Nov
PMID:Recurrent pyoderma gangrenosum and agnogenic myeloid metaplasia. 93 1

A variety of c-DNAs coding for nuclear retinoic acid receptors (RARs) have recently been cloned. These receptors are members of the steroid/thyroid receptor superfamily and are believed to act as ligand-inducible transactivating factors; retinoic acid induces changes in receptor configuration that allows DNA binding and increased gene transcription from specific genes to occur. The retinoic acid receptor family itself may consist of up to 20 separate receptors each with a specific distribution and ligand binding characteristics. The RAR-gamma in the adult is found almost exclusively in the skin but other receptors which are found in a variety of other tissues are also present in skin. Associations of cutaneous disease states with receptor mutants have not yet been reported although some cases of leukaemia may be secondary to retinoic acid receptor gene rearrangements. A variety of approaches to identify the biological function of these receptors based on recombinant DNA technology are already underway.
Br J Dermatol 1992 Feb
PMID:The molecular biology of retinoic acid receptors: orphan from good family seeks home. 131 Nov 93


1 2 3 4 5 6 7 8 9 10 Next >>